• Je něco špatně v tomto záznamu ?

Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

M. Štach, R. Pytlík, K. Šmilauerová, J. Rychlá, M. Mucha, J. Musil, A. Koladiya, M. Nemec, M. Petráčková, I. Kaštánková, P. Pecherková, L. Šrámková, K. Polgárová, M. Trněný, P. Lesný, J. Vydra, P. Otáhal

. 2023 ; 29 (-) : 1610914. [pub] 20230420

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011738

Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-clinical trial conditions. The goal was to determine how the intensive pretreatment of patients affects the produced CAR-T cells, their in vivo expansion, and the outcome of the therapy. Multiparametric flow cytometry was used to analyze the material used for manufacturing CAR-T cells (apheresis), the CAR-T cell product itself, and blood samples obtained at three timepoints after administration. We present the analysis of memory phenotype of CD4/CD8 CAR-T lymphocytes (CD45RA, CD62L, CD27, CD28) and the expression of inhibitory receptors (PD-1, TIGIT). In addition, we show its relation to the patients' clinical characteristics, such as tumor burden and sensitivity to prior therapies. Patients who responded to therapy had a higher percentage of CD8+CD45RA+CD27+ T cells in the apheresis, although not in the produced CAR-Ts. Patients with primary refractory aggressive B-cell lymphomas had the poorest outcomes which was characterized by undetectable CAR-T cell expansion in vivo. No clear correlation of the outcome with the immunophenotypes of CAR-Ts was observed. Our results suggest that an important parameter predicting therapy efficacy is CAR-Ts' level of expansion in vivo but not the immunophenotype. After CAR-T cells' administration, measurements at several timepoints accurately detect their proliferation intensity in vivo. The outcome of CAR-T cell therapy largely depends on biological characteristics of the tumors rather than on the immunophenotype of produced CAR-Ts.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011738
003      
CZ-PrNML
005      
20231102132502.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/pore.2023.1610914 $2 doi
035    __
$a (PubMed)37151356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Štach, Martin $u Institute of Hematology and Blood Transfusion, Praha, Czechia $u Faculty of Science, Charles University, Praha, Czechia
245    10
$a Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome / $c M. Štach, R. Pytlík, K. Šmilauerová, J. Rychlá, M. Mucha, J. Musil, A. Koladiya, M. Nemec, M. Petráčková, I. Kaštánková, P. Pecherková, L. Šrámková, K. Polgárová, M. Trněný, P. Lesný, J. Vydra, P. Otáhal
520    9_
$a Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-clinical trial conditions. The goal was to determine how the intensive pretreatment of patients affects the produced CAR-T cells, their in vivo expansion, and the outcome of the therapy. Multiparametric flow cytometry was used to analyze the material used for manufacturing CAR-T cells (apheresis), the CAR-T cell product itself, and blood samples obtained at three timepoints after administration. We present the analysis of memory phenotype of CD4/CD8 CAR-T lymphocytes (CD45RA, CD62L, CD27, CD28) and the expression of inhibitory receptors (PD-1, TIGIT). In addition, we show its relation to the patients' clinical characteristics, such as tumor burden and sensitivity to prior therapies. Patients who responded to therapy had a higher percentage of CD8+CD45RA+CD27+ T cells in the apheresis, although not in the produced CAR-Ts. Patients with primary refractory aggressive B-cell lymphomas had the poorest outcomes which was characterized by undetectable CAR-T cell expansion in vivo. No clear correlation of the outcome with the immunophenotypes of CAR-Ts was observed. Our results suggest that an important parameter predicting therapy efficacy is CAR-Ts' level of expansion in vivo but not the immunophenotype. After CAR-T cells' administration, measurements at several timepoints accurately detect their proliferation intensity in vivo. The outcome of CAR-T cell therapy largely depends on biological characteristics of the tumors rather than on the immunophenotype of produced CAR-Ts.
650    _2
$a lidé $7 D006801
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a receptory antigenů T-buněk $x metabolismus $7 D011948
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a CD8-pozitivní T-lymfocyty $x metabolismus $7 D018414
650    12
$a B-buněčný lymfom $7 D016393
650    12
$a difúzní velkobuněčný B-lymfom $x patologie $7 D016403
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pytlík, Robert $u Institute of Hematology and Blood Transfusion, Praha, Czechia $u First Faculty of Medicine, Charles University, Praha, Czechia
700    1_
$a Šmilauerová, Kristýna $u Institute of Hematology and Blood Transfusion, Praha, Czechia $u Faculty of Science, Charles University, Praha, Czechia
700    1_
$a Rychlá, Jana $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Mucha, Martin $u Institute of Hematology and Blood Transfusion, Praha, Czechia $u Faculty of Science, Charles University, Praha, Czechia
700    1_
$a Musil, Jan $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Koladiya, Abhishek $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Nemec, Matěj $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Petráčková, Martina $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Kaštánková, Iva $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Praha, Czechia $d 1980- $7 ctu2013787641
700    1_
$a Šrámková, Lucie $u Second Faculty of Medicine (2. LF UK), University Hospital in Motol, Praha, Czechia
700    1_
$a Polgárová, Kamila $u First Faculty of Medicine, Charles University, Praha, Czechia $u General University Hospital in Prague, Praha, Czechia
700    1_
$a Trněný, Marek $u First Faculty of Medicine, Charles University, Praha, Czechia $u General University Hospital in Prague, Praha, Czechia
700    1_
$a Lesný, Petr $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Praha, Czechia
700    1_
$a Otáhal, Pavel $u Institute of Hematology and Blood Transfusion, Praha, Czechia $u First Faculty of Medicine, Charles University, Praha, Czechia
773    0_
$w MED00180530 $t Pathology oncology research $x 1532-2807 $g Roč. 29, č. - (2023), s. 1610914
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37151356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20231102132457 $b ABA008
999    __
$a ok $b bmc $g 1963905 $s 1198003
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c - $d 1610914 $e 20230420 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace